Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia

Human Psychopharmacology
Tomomi TenjinNoboru Yamaguchi

Abstract

The purpose of this study was to evaluate the effects of blonanserin, a novel antipsychotic, on cognitive function in first-episode schizophrenia. Twenty-four antipsychotic-naïve patients with first-episode schizophrenia participated in the study. Blonanserin was given in an open-label design for 8 weeks. The Brief Assessment of Cognition in Schizophrenia-Japanese language version (BACS-J) was administered as the primary outcome measure at baseline and 8 weeks. Clinical evaluation included the Positive and Negative Syndrome Scale (PANSS), the Schizophrenia Quality of Life Scale-Japanese language version (SQLS-J), and the Clinical Global Impression-Severity of Illness Scale (CGI-S). To exclude the possibility of retest effects on the BACS-J, 10 age-matched patients with chronic schizophrenia treated with blonanserin were tested at baseline and after an 8-week interval. Twenty first-episode patients completed the study. Repeated measures analysis of covariance revealed a significant group-by-time interaction effect on the letter fluency task due to better performance in the first-episode group, but not in the control group. Main effect of time or group-by-time interaction effect on the Tower of London task was not significant; ho...Continue Reading

References

Mar 1, 1991·The British Journal of Psychiatry : the Journal of Mental Science·P F Liddle, D L Morris
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Feb 1, 1994·Archives of General Psychiatry·A J SaykinR C Gur
Dec 1, 1993·The British Journal of Psychiatry : the Journal of Mental Science·H A AllenC D Frith
Mar 1, 1996·The American Journal of Psychiatry·Michael F Green
Feb 1, 1996·The European Journal of Neuroscience·A M OwenA C Evans
Jun 1, 1996·Neuropsychologia·S C BakerT W Robbins
Jan 1, 1996·Schizophrenia Bulletin·T K LarsenL C Moe
Mar 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·H Y MeltzerR Ranjan
Mar 30, 2000·The American Journal of Psychiatry·Robert M BilderJ A Lieberman
Apr 29, 2000·Schizophrenia Research·E HowanitzPhilip D Harvey
Aug 17, 2000·The British Journal of Psychiatry : the Journal of Mental Science·G WilkinsonC Jenkinson
Feb 7, 2001·The American Journal of Psychiatry·Philip D Harvey, Richard S E Keefe
Jun 14, 2002·Biological Psychiatry·William T Carpenter, James M Gold
Dec 7, 2002·Psychiatry Research·Yasuhiro KanedaTetsuro Ohmori
Sep 27, 2003·Schizophrenia Research·Christina E Bokat, Terry E Goldberg
Apr 28, 2006·Schizophrenia Bulletin·Dawn I VelliganJames M Gold
Jun 6, 2007·Archives of General Psychiatry·Richard S E KeefeNeurocognitive Working Group
Jul 13, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Richard S E KeefeRobert S Goldman
Sep 22, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Mié MatsuiMasayoshi Kurachi
Dec 18, 2007·Psychiatry and Clinical Neurosciences·Yasuhiro KanedaTetsuro Ohmori
May 17, 2008·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Simona AnselmettiRoberto Cavallaro
Dec 5, 2008·European Archives of Psychiatry and Clinical Neuroscience·Wolfgang WölwerGerman Study Group on First Episode Schizophrenia
May 6, 2009·Neuropsychology·Raquelle I Mesholam-GatelyLarry J Seidman
Sep 11, 2009·CNS Drugs·Kayvon SalimiJ A Lieberman
Dec 22, 2009·Expert Review of Neurotherapeutics·S Kristian HillJohn A Sweeney
Dec 25, 2009·CNS Drugs·Emma D Deeks, Gillian M Keating
Jan 22, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Terry E GoldbergPhilip D Harvey
Jan 30, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Puay San WoonKang Sim
Aug 21, 2010·Schizophrenia Research·Nicoletta M J van VeelenRené S Kahn
Sep 11, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Shin OginoNoboru Yamaguchi
Dec 15, 2010·CNS Spectrums·Delbert Robinson
Feb 16, 2011·The Australian and New Zealand Journal of Psychiatry·Vasilis P Bozikas, Christina Andreou

Citations

Apr 3, 2013·European Journal of Clinical Pharmacology·Melvin GeorgeSteven Aibor Dkhar
Jun 15, 2013·Neuropsychiatric Disease and Treatment·Tomomi TenjinNoboru Yamaguchi
Dec 21, 2013·Expert Opinion on Pharmacotherapy·Naren P Rao, Gary Remington
Apr 4, 2015·Journal of Pharmacological Sciences·Satoko BabaMichiko Ono
Aug 15, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Hirotake HidaYukihiro Noda
May 20, 2014·Psychiatry and Clinical Neurosciences·Yuriko NinomiyaNoboru Yamaguchi

Related Concepts

Lonasen
Chronic Disease
Overinclusion
Piperazines
Piperidines
Factor Construct Rating Scales (Fcrs)
Quality of Life
Schizophrenia
Severity of Illness Index
Antipsychotic Effect

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here